@article{JTD16503,
author = {Marika Cinausero and Karim Rihawi and Francesca Sperandi and Barbara Melotti and Andrea Ardizzoni},
title = {Chemotherapy treatment in malignant pleural mesothelioma: a difficult history},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 2},
year = {2017},
keywords = {},
abstract = {Malignant pleural mesothelioma (MPM) is a rare neoplasm that typically arises from mesothelial surfaces of the pleural cavity. Despite treatment improvements, it carries a dismal prognosis. The majority of patients either have unresectable disease or are not candidates for surgery due to medical comorbidities or old age. For such patients, chemotherapy (CT) represents the gold-standard treatment. To date, combination CT with cisplatin plus pemetrexed represents the most widely used regimen in first-line setting for patients with unresectable MPM. Other first-line options are currently available, including the use of raltitrexed instead of pemetrexed combined with platinum. In this review, we discuss the role of CT in MPM mainly focusing on the results of the trials conducted in first-line setting.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/16503}
}